01758nas a2200361   4500000000100000008004100001260003800042653000900080653002500089653002500114653001500139653001100154653002100165653002900186653001900215653001200234653002500246653003700271653003200308100001400340700001600354700001300370700001700383700001800400700001700418700001400435245008500449300001000534490000700544050001700551520081400568022001401382       2012                            d  c2012 FebbSpringer LondonaLondon10aAged10aAntirheumatic Agents10aArthritis, Psoriatic10aEtanercept10aHumans10aImmunoglobulin G10aImmunosuppressive Agents10aLeper Colonies10aleprosy10aLeprosy, lepromatous10aReceptors, Tumor Necrosis Factor10aTumor Necrosis Factor-alpha1 aLydakis C1 aIoannidou D1 aKoumpa I1 aGiannikaki E1 aThalassinos E1 aKrasoudaki E1 aMiyakis S00aDevelopment of lepromatous leprosy following etanercept treatment for arthritis.  a395-80 v31  aLYDAKIS 20113 a<p>We present a case of a patient treated with etanercept (TNF-a antagonist) for psoriatic arthritis, who then developed clinical symptoms of lepromatous leprosy. She presented with multiple erythematous plaques on trunk, face and extremities, saddle nose deformity, alopecia, articular deformities of the feet and peroneal neuropathy. The clinical suspicion of Hansen's Disase was confirmed by the biopsy findings (lepromatous leprosy). On further questioning, the patient stated that her father was diagnosed with leprosy 70 years ago and had spent some years in a leper colony in Spinalonga island in Southern Greece in the 1940s. This first report of Hansen's disease after administration of etanercept highlights the need of careful risk assessment of patients for whom antiTNF treatment is planned.</p>  a1434-9949